Darapladib is primarily used in the research and development of treatments for cardiovascular diseases, particularly atherosclerosis. It functions by inhibiting the enzyme lipoprotein-associated phospholipase A2 (Lp-PLA2), which plays a key role in vascular inflammation and plaque buildup in arteries. By reducing inflammatory processes within arterial walls, Darapladib aims to stabilize atherosclerotic plaques and prevent their rupture, a major cause of heart attacks and strokes. It has been investigated in clinical trials for its potential to reduce the risk of major cardiovascular events in patients with existing heart disease. Though not widely approved for clinical use, it remains a significant compound in studying anti-inflammatory approaches to managing atherosclerosis.